Edgestream Partners L.P. lifted its stake in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 170.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 186,588 shares of the company's stock after purchasing an additional 117,506 shares during the period. Edgestream Partners L.P. owned about 0.22% of Progyny worth $3,219,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds have also recently modified their holdings of PGNY. Pacer Advisors Inc. grew its position in shares of Progyny by 12,579.4% in the third quarter. Pacer Advisors Inc. now owns 2,492,642 shares of the company's stock valued at $41,777,000 after purchasing an additional 2,472,983 shares in the last quarter. Invenomic Capital Management LP acquired a new stake in Progyny during the third quarter worth about $29,509,000. Fort Washington Investment Advisors Inc. OH raised its stake in Progyny by 90.1% during the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 1,467,780 shares of the company's stock worth $25,319,000 after purchasing an additional 695,740 shares during the period. Barclays PLC grew its stake in shares of Progyny by 530.4% in the 3rd quarter. Barclays PLC now owns 706,157 shares of the company's stock valued at $11,835,000 after buying an additional 594,140 shares during the period. Finally, Point72 Asset Management L.P. increased its holdings in shares of Progyny by 227.8% during the 3rd quarter. Point72 Asset Management L.P. now owns 789,418 shares of the company's stock worth $13,231,000 after buying an additional 548,602 shares during the last quarter. Institutional investors and hedge funds own 94.93% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities research analysts have issued reports on PGNY shares. Truist Financial reissued a "hold" rating and set a $19.00 target price (down previously from $26.00) on shares of Progyny in a research note on Wednesday, November 13th. Bank of America upped their target price on shares of Progyny from $21.00 to $25.00 and gave the company a "buy" rating in a research report on Tuesday, February 11th. JPMorgan Chase & Co. lifted their target price on shares of Progyny from $17.00 to $23.00 and gave the company a "neutral" rating in a report on Tuesday, January 28th. Canaccord Genuity Group boosted their price objective on Progyny from $17.00 to $23.00 and gave the company a "hold" rating in a report on Friday, February 28th. Finally, Barclays cut their price target on Progyny from $30.00 to $17.00 and set an "overweight" rating on the stock in a report on Thursday, November 14th. Nine equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $24.82.
Get Our Latest Research Report on PGNY
Progyny Trading Up 0.4 %
Shares of PGNY traded up $0.08 during midday trading on Wednesday, reaching $20.03. 1,936,967 shares of the company were exchanged, compared to its average volume of 1,925,772. Progyny, Inc. has a 1-year low of $13.39 and a 1-year high of $38.98. The company has a market cap of $1.71 billion, a price-to-earnings ratio of 34.54, a P/E/G ratio of 2.39 and a beta of 1.41. The stock has a 50-day moving average price of $21.43 and a 200-day moving average price of $18.65.
Insider Activity
In other Progyny news, Chairman David J. Schlanger purchased 150,000 shares of the business's stock in a transaction that occurred on Thursday, December 26th. The shares were acquired at an average price of $14.68 per share, for a total transaction of $2,202,000.00. Following the completion of the purchase, the chairman now owns 228,269 shares in the company, valued at $3,350,988.92. The trade was a 191.65 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Peter Anevski purchased 209,500 shares of Progyny stock in a transaction that occurred on Monday, December 23rd. The stock was acquired at an average cost of $14.48 per share, with a total value of $3,033,560.00. Following the acquisition, the chief executive officer now directly owns 441,463 shares of the company's stock, valued at $6,392,384.24. The trade was a 90.32 % increase in their position. The disclosure for this purchase can be found here. Insiders own 12.30% of the company's stock.
About Progyny
(
Free Report)
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
Further Reading

Before you consider Progyny, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Progyny wasn't on the list.
While Progyny currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.